NEWTON, Mass., March 14, 2019 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act…Original Article
Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
